Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”-Reference-Cited by-同舟云学术

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

Published:2022-04-07 Issue:4 Volume:12 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Begna K. H.^ORCID,Xu X.,Gangat N.^ORCID,Alkhateeb H.^ORCID,Patnaik M. M.^ORCID,Al-Kali A.^ORCID,Elliott M. A.,Hogan W. J.^ORCID,Litzow M. R.^ORCID,Hook C. C.,Wolanskyj-Spinner A. P.,Mangaonkar A.^ORCID,He R.^ORCID,Pardanani A.,Shah M.^ORCID,Ketterling R. P.,Tefferi A.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-022-00654-0.pdf

Reference12 articles.

1. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–75.

2. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087–94.

3. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135:165–73.

4. Borthakur G, Kantarjian H, Wang X, Plunkett WK Jr, Gandhi VV, Faderl S, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer 2008;113:3181–5.

5. Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, et al. Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. Hematol Rep. 2017;9:7029.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia;eJHaem;2024-07-24

2. Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia;Blood Cancer Journal;2024-06-24

3. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11);International Journal of Hematology;2023-11-28

4. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment;Blood Reviews;2023-11

5. Therapy-related core binding factor acute myeloid leukemia;International Journal of Hematologic Oncology;2023-03